In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...

Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Wells Fargo CEO Charlie Scharf validates some of the optimism, telling analysts he feels "really great about our progress." ...

We recently compiled a list of the 7 Stocks That Could Surge From LA Wildfires Recovery Efforts. In this article, we are ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

RBC says it already uses AI in customer service, staff guidance, and to help the productivity of research analysts in its capital markets business, while TD says it uses AI to help its call centre ...

Fintel reports that on January 7, 2025, RBC Capital upgraded their outlook for Carvana (NYSE:CVNA) from Sector Perform to Outperform. Analyst Price Forecast Suggests 30.86% Upside As of December ...

Acknowledging that there is skepticism surrounding its business model and ability to sustain profitability targets, RBC Capital joins the growing list of bulls in support of Carvana, raising its ...

Investing.com -- RBC Capital Markets on Monday upgraded Carvana (NYSE:CVNA) shares to Outperform, and lifted the target price to $280 from $270. According to the firm’s analysts, following ...